These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 1655118)
21. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509 [TBL] [Abstract][Full Text] [Related]
22. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex. Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981 [TBL] [Abstract][Full Text] [Related]
23. DNA-topoisomerase I and II: biologic features and their role in drug resistance. Russo D; Marie JP; Delmer A; Zhou D; Suberville AM; Baccarani M; Zittoun R Haematologica; 1993; 78(4):201-7. PubMed ID: 8294050 [No Abstract] [Full Text] [Related]
24. The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies. Boege F; Gieseler F; Biersack H; Meyer P Eur J Clin Chem Clin Biochem; 1992 Feb; 30(2):63-8. PubMed ID: 1316175 [TBL] [Abstract][Full Text] [Related]
25. [Mechanisms of resistance to DNA topoisomerase II inhibitors]. Kohno K; Takano H; Kuwano M Gan To Kagaku Ryoho; 1991 Aug; 18(10):1568-73. PubMed ID: 1651684 [TBL] [Abstract][Full Text] [Related]
26. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA. Lin JH; Castora FJ Arch Biochem Biophys; 1995 Dec; 324(2):293-9. PubMed ID: 8554321 [TBL] [Abstract][Full Text] [Related]
27. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Nitiss JL; Liu YX; Hsiung Y Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128 [TBL] [Abstract][Full Text] [Related]
28. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine. Nitiss JL; Vilalta PM; Wu H; McMahon J Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059 [TBL] [Abstract][Full Text] [Related]
29. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144 [TBL] [Abstract][Full Text] [Related]
30. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines. Robson CN; Hoban PR; Harris AL; Hickson ID Cancer Res; 1987 Mar; 47(6):1560-5. PubMed ID: 2434220 [TBL] [Abstract][Full Text] [Related]
31. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine. Sorensen M; Sehested M; Jensen PB Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525 [TBL] [Abstract][Full Text] [Related]
32. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Friche E; Danks MK; Schmidt CA; Beck WT Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312 [TBL] [Abstract][Full Text] [Related]
33. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents. Hsiung Y; Jannatipour M; Rose A; McMahon J; Duncan D; Nitiss JL Cancer Res; 1996 Jan; 56(1):91-9. PubMed ID: 8548781 [TBL] [Abstract][Full Text] [Related]
34. Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells. Del Bino G; Darzynkiewicz Z Cancer Res; 1991 Feb; 51(4):1165-9. PubMed ID: 1997159 [TBL] [Abstract][Full Text] [Related]
35. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
36. The mechanism of epipodophyllotoxin-induced thymocyte apoptosis: possible role of a novel Ca(2+)-independent protein kinase. Ye X; Georgoff I; Fleisher S; Coffman FD; Cohen S; Fresa KL Cell Immunol; 1993 Oct; 151(2):320-35. PubMed ID: 8402939 [TBL] [Abstract][Full Text] [Related]
37. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity. Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768 [TBL] [Abstract][Full Text] [Related]
38. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs. Epstein RJ; Smith PJ Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970 [TBL] [Abstract][Full Text] [Related]
39. [Antitumor agents targeting mammalian topoisomerases]. Nakano H Gan To Kagaku Ryoho; 1991 Aug; 18(10):1550-5. PubMed ID: 1651681 [TBL] [Abstract][Full Text] [Related]
40. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Jensen PB; Sørensen BS; Sehested M; Grue P; Demant EJ; Hansen HH Cancer Res; 1994 Jun; 54(11):2959-63. PubMed ID: 8187081 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]